FDA Wants Your Data to Tweak Over-the-Counter Rules
Published Date: 7/16/2026
Notice
Summary
The FDA is rolling out a clear process to ask the public for data to help update rules about over-the-counter (OTC) drugs. This means anyone interested in OTC drug safety and use can share info that might change how these medicines are regulated. The new process starts now and aims to make drug updates smarter and faster, with no direct costs to the public but big benefits for safer medicines.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Public data submissions for OTC monographs
Starting July 16, 2026, FDA will announce Data Requests on the OTC Monographs@FDA portal (https://www.accessdata.fda.gov/scripts/cder/omuf/). The public may submit data and information in response to those Data Requests to help inform certain future over‑the‑counter (OTC) monograph drug activities.
Submission confidentiality and notification process
Each Data Request will include instructions on how to submit data, how confidential information will be handled, and how submissions may be viewed by the public. FDA also intends to list planned Data Requests in its Annual Forecast for Planned Monograph Activities (a nonbinding 3‑year list) and offers an email mailing list on the OTC Monographs@FDA portal for alerts.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17812, Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that NAMENDA (memantine hydrochloride) tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as the ANDAs meet relevant legal and regulatory requirements.
2026-17659, Rahim Shafa; Denial of Hearing; Final Debarment Order
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Rahim Shafa (Dr. Shafa) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Dr. Shafa from providing services in any capacity to a person that has an approved or pending drug product application and debarring Dr. Shafa for 20 years from importing or offering for import any drug into the United States. FDA bases this order on the findings that Dr. Shafa was convicted of multiple felonies under Federal law that relate to the regulation of any drug product under the FD&C Act and the importation into the United States of any drug or controlled substance under the FD&C Act. FDA provided notice to Dr. Shafa of the proposed debarment and an opportunity to request a hearing. Dr. Shafa submitted a request for a hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
2026-17676, Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection pertaining to the registration of human drug compounding outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and associated fees.
Previous / Next Documents
Previous: 2026-14280, Importer of Controlled Substances Application: Catalent CTS, LLC
Catalent CTS, LLC wants to become an official importer of certain controlled substances like marijuana and gamma hydroxybutyric acid. People and companies involved can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or changes for the public are mentioned yet.
Next: 2026-14284, Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals LLC
AMPAC Fine Chemicals LLC wants to become a big-time maker of certain controlled drugs like amphetamine and methylphenidate. This means they’ll handle large amounts of these substances, which are mostly used in medicines. People and companies can share their thoughts or ask for a hearing by September 14, 2026, so don’t miss the deadline!